Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

23Andme Holding Co. (ME)

23Andme Holding Co. (ME)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 172,015
  • Shares Outstanding, K 482,917
  • Annual Sales, $ 299,490 K
  • Annual Income, $ -311,660 K
  • 60-Month Beta 1.27
  • Price/Sales 0.68
  • Price/Cash Flow N/A
  • Price/Book 0.51
Trade ME with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.69
  • Most Recent Earnings $-0.17 on 02/07/24
  • Latest Earnings Date 05/23/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 222.91% ( +59.94%)
  • Historical Volatility 130.20%
  • IV Percentile 99%
  • IV Rank 86.34%
  • IV High 255.03% on 02/16/24
  • IV Low 19.85% on 01/16/24
  • Put/Call Vol Ratio 0.17
  • Today's Volume 7,479
  • Volume Avg (30-Day) 881
  • Put/Call OI Ratio 0.11
  • Today's Open Interest 41,154
  • Open Int (30-Day) 39,725

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr N/A
See More
  • Average Estimate N/A
  • Number of Estimates N/A
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.3500 +42.11%
on 04/17/24
0.6190 -19.64%
on 04/18/24
+0.0265 (+5.63%)
since 03/18/24
3-Month
0.3500 +42.11%
on 04/17/24
0.8260 -39.78%
on 02/16/24
-0.1726 (-25.76%)
since 01/18/24
52-Week
0.3500 +42.11%
on 04/17/24
2.2100 -77.49%
on 05/10/23
-1.5626 (-75.85%)
since 04/18/23

Most Recent Stories

More News
Billionaires Are Snapping Up Beaten-Down 23andMe Stock. Should You Follow Their Lead?

Several well-regarded funds run by famous billionaire investors bought shares of 23andMe during the last three months of 2023.

ME : 0.5006 (+40.54%)
GSK : 39.25 (-0.88%)
A Few Years From Now, You'll Probably Wish You'd Followed Billionaire Investors Into This Stock

Nu Holdings went from an idea to a $50 billion business over a handful of years. Several billionaire investors are betting on even more upside.

BRK.AX : 0.014 (unch)
SQ : 72.14 (-1.86%)
SNOW : 148.01 (-0.53%)
META : 501.14 (+1.41%)
AAPL : 166.96 (-0.62%)
OKTA : 93.62 (-0.19%)
ZM : 59.89 (+1.37%)
ABNB : 159.95 (+1.00%)
DASH : 130.00 (-0.69%)
ME : 0.5006 (+40.54%)
CART : 36.53 (+0.50%)
NU : 10.68 (-1.02%)
Is 23andMe Stock a Smart Buy Right Now?

It's having trouble getting its core business model to work.

ME : 0.5006 (+40.54%)
The 3 Worst Stock Investments I Ever Made -- and What I Learned From Them

Not all of my investments have been winners. Here are three that went badly and the important lessons I learned from them.

ME : 0.5006 (+40.54%)
LTCH : 0.5101 (-15.00%)
AAPL : 166.96 (-0.62%)
TSLA : 150.70 (-3.06%)
IBM : 181.23 (-1.02%)
SHOP : 69.52 (+0.16%)
MELI : 1,376.78 (-1.51%)
T : 16.25 (+0.81%)
INVESTIGATION ALERT: Levi & Korsinsky, LLP Announces Investigation Of 23andMe Holding Co (ME) Data Breach

New York, New York--(Newsfile Corp. - December 7, 2023) - 23andMe, a popular personal genomics and DNA analysis company run by 23andMe Holding Co. ("23 and Me") (NASDAQ: ME), recently suffered a massive...

ME : 0.5006 (+40.54%)
Why Pancreatic Cancer is No Longer a Death Sentence: Emerging Therapies to Watch

USA News Group – Despite being a relatively rare form of cancer, pancreatic cancer remains one of the deadliest in the oncology field, the third leading cause of cancer death in the USA. Still not fully...

ONCY : 1.0300 (-0.96%)
ONC.TO : 1.43 (-0.69%)
LLY : 743.89 (-0.92%)
RHHBY : 29.9700 (-0.37%)
BNTX : 86.01 (-0.45%)
ME : 0.5006 (+40.54%)
Fighting the Silent Killer: Innovative Therapies for Pancreatic Cancer on the Rise

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(OTCQX:RHHBY),(NASDAQ:BNTX),(NASDAQ:ME) EQNX::TICKER_END

LLY : 743.89 (-0.92%)
ONCY : 1.0300 (-0.96%)
ONC.TO : 1.43 (-0.69%)
RHHBY : 29.9700 (-0.37%)
BNTX : 86.01 (-0.45%)
ME : 0.5006 (+40.54%)
Better AI Biotech Stock: Recursion Pharmaceuticals vs. 23andMe

Both businesses have a lot to prove.

RXRX : 7.45 (-0.27%)
ME : 0.5006 (+40.54%)
Why 23andMe Holding Stock Plummeted by 13% Today

Investors reacted sharply and not well to the company's inaugural set of fiscal 2024 earnings.

ME : 0.5006 (+40.54%)
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating 23andMe Holding Co. for Potential Breaches of Fiduciary Duty By Its Board of Directors

/PRNewswire/ -- Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of...

ME : 0.5006 (+40.54%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

23andMe Inc. is a consumer genetics and research company. It involved in discovery programs rooted in human genetics across a spectrum of disease areas, including oncology, respiratory and cardiovascular diseases, in addition to other therapeutic areas. 23andMe Inc., formerly known as VG Acquisition...

See More

Key Turning Points

3rd Resistance Point 0.4433
2nd Resistance Point 0.4234
1st Resistance Point 0.3898
Last Price 0.5006
1st Support Level 0.3363
2nd Support Level 0.3164
3rd Support Level 0.2828

See More

52-Week High 2.2100
Fibonacci 61.8% 1.4995
Fibonacci 50% 1.2800
Fibonacci 38.2% 1.0605
Last Price 0.5006
52-Week Low 0.3500

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar